133b targeted 3'-UTR of the specificity protein 1 (SP1). ChIP assay demonstrated that SP1 can interact with the GC-rich region in the MYPT1 promoter and CPI-17 gene promoters were governed by the proximal GC-boxes, where SP1 transcription factors bound. Upregulation of miR-133b could down-regulate the expression of SP1, dramatically revert HG-induced phosphorylation level of MYPT1 at The853 of MLCP and CPI-17 at Thr38. In vivo experiment exhibited erectile function in miR-133b agomir group was markedly increased in the diabetic rats compared with the negative control groups and diabetic ED group. Mechanistically, consistented with in vitro experiments, miR-133b supplementation induced relaxation of the CCSM via nitric oxide-independent pathways. CONCLUSIONS: Three miRs were found in diabetic ED rat model. The present results indicate that miR-133b supplementation could improve erectile function in diabetic ED rats probably by regulating the contractility of CCSM via myosin light chain phosphatase inhibition. Neuronal injury from prostate cancer treatments, such as radical prostatectomy (RP) and androgen deprivation therapy (ADT), are implicated in erectile dysfunction (ED). Nerve injury from RP during periods of low T increases the incidence and severity of ED. Our objectives were to: 1) examine the effects of bilateral cavernous nerve injury (BCNI) during T deprivation on both erections and major pelvic ganglia (MPG) neuron survival, growth, and regeneration; and 2) assess if T supplementation restores erections and MPG health.
INTRODUCTION AND OBJECTIVES: Testosterone (T) is
essential to maintain neuron health and to recover from neuropraxia. Neuronal injury from prostate cancer treatments, such as radical prostatectomy (RP) and androgen deprivation therapy (ADT), are implicated in erectile dysfunction (ED). Nerve injury from RP during periods of low T increases the incidence and severity of ED. Our objectives were to: 1) examine the effects of bilateral cavernous nerve injury (BCNI) during T deprivation on both erections and major pelvic ganglia (MPG) neuron survival, growth, and regeneration; and 2) assess if T supplementation restores erections and MPG health.
METHODS: Male Sprague-Dawley rats (12 wks, n[9/grp) were separated into 5 groups: control (CON); castrated (CAST); BCNI; CAST and BCNI (CþB); CAST, BCNI and T supplementation (CþBþT). CAST was performed at 12 weeks, and BCNI and T supplementation (3 mg/kg/day) began at 16 weeks. At 18 weeks, erections were assessed by cavernous nerve stimulated intracavernosal to mean arterial pressure (ICP/MAP). MPG neurons were dissociated, cultured and stained for beta-tubulin, TUNEL assay and neuronal nitric oxide synthase (nNOS) to assess length, branching, apoptosis and nitrergic neurons (n[4/grp). MPG gene expression of beta-tubulin (TUBB3), nNOS (NOS1), Schwann cells (GFAP), markers of nerve injury (ATF3) and regeneration (GAP43) was measured (n[5/grp).
RESULTS: CAST and BCNI lowered ICP/MAP; however CþB resulted in further decreased ICP (p<0.01). Cultured MPG neurons from BCNI and CAST had increased apoptosis, but apoptosis was highest in CþB (p<0.01). Compared to CON, BCNI, CAST and CþB demonstrated decreased neurite branching and nitrergic neurons (p<0.05) while neurite length was unchanged. MPG gene expression of activated Schwann cells (GFAP) was greatly increased after nerve injury in both androgen intact and deprived rats (p<0.01). nNOS positive neurons were decreased while markers of nerve injury and repair (ATF3, GAP43) and TUBB3 were unchanged. T supplementation in CþB rats markedly improved erectile function, suppressed neuronal apoptosis, and increased nNOS neurons (p<0.01). Additionally, T decreased GFAP and increased NOS1 gene expression (p<0.01).
CONCLUSIONS: The combination of ADT and BCNI caused severe ED and markedly impaired neuronal health. Low T leaves post-RP nerves highly susceptible to increased apoptosis and Schwann cell activation. T supplementation rescued erections, improved neuron health and should be considered for prostate cancer survivors with urogenital dysfunction. (J Androl 2009, 30: 370) . In fact, hyperinsulinemia and obesity inhibit testicular testosterone production (Nat Rev Endocrinol 2009, 5: 673) . Male Otsuka Long-Evans Tokushima Fatty (OLETF) rats fed a normal chow show MetS. Tadalafil was suggested to increase testosterone levels in patients with erectile dysfunction (Clin Endocrinol 2004, 61: 382; J Sex Med 2008 , 5:1482 , We used OLETF rats as a model of MetS and LETO rats as a control to investigate the effect of tadalafil on the levels of testosterone and estradiol, and mounting behavior.
METHODS: We treated 36-week-old male OLETF and LETO rats with oral tadalafil (100 mg/kg/day) for 12 weeks, whereas the sham groups received only vehicle for 12 weeks. Before and after the 12-week tadalafil treatment, the serum levels of total and free testosterone and estradiol were compared among four treatment groups. Serum testosterone and estradiol levels were monitored with a rat ELISA kit. Copulatory disorder was examined by matching each rat to an estrous female.
RESULTS: The testosterone level was significantly lower in the OLETF groups vs. the LETO groups at 36 weeks. After the 12-week tadalafil treatment, the levels of total and free testosterone were both significantly increased in the OLETF-tadalafil group vs. the OLETFvehicle group, and also increased in the LETO-tadalafil vs. LETOvehicle (Fig.1) . Tadalafil treatment decreased the estradiol levels in both the OLETF and LETO rats (Fig2). A significant suppression of mounting behavior, that is, elongation of intromission latency, was found in OLETF rats, however, 12-week tadarafil treatment prevented the mounting ability from worsening.
